Anapharm Bioanalytics is proud to announce that it has recently renewed its ANVISA (Brazil) certificate.
The renewed certification is valid until 11th June 2020.
After the corresponding regulatory inspection Anapharm Bioanalytics has renewed once more its Certificate for Good Laboratory Practice Principles (GLP). The company is under GLP certification since its foundation. The present certificate is valid until June 2020.
The presentation of our Bioanalytical Coordinator, Araceli Castillo, was focused on two trending topics on Bioanalysis: the final guidance on Bioanalytical Method Validation published by the US FDA on May 21st, 2018 and the progress on the new guideline ICH M10 for the harmonization of bioanalytical method validation.
Anapharm Bioanalytics has successfully developed and validated a bioanalytical method for determination of Unconjugated Estradiol and Estrone in human plasma by LC-MS/MS.
We are pleased to announce that as part of our rebranding strategy, our brand name has now changed from Anapharm Europe to Anapharm Bioanalytics.
Anapharm Europe is proud to announce that it has successfully undergone its first US FDA inspection at its Barcelona based bioanalytical lab.
Anapharm Europe is proud to announce that it has recently renewed its ANVISA (Brazil) certificate.
Anapharm Europe has renewed its certification to offer the advantages of the French research tax credit (crédit d’impôt recherche) for period 2015 – 2019.
Anapharm Biotech, the peptide and protein chemistry division of Anapharm Europe, has completed method development of biomarkers Anti-IIa, Anti-Xa and TPFI in human plasma by chromogenic assays and ELISA, respectively.